 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jul 19, 2016 |
| Title |
HLA peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Treatment of cancer cells with anti-cancer drugs often fails to achieve complete remission. Yet, such drug treatments may induce alteration in the tumor’s gene expression patterns, including those of Cancer/Testis Antigens (CTA). The degradation products of such antigens can be presented as HLA peptides on the surface of the tumor cells and be developed into anti-cancer immunotherapeutics. For example, the DNA methyl transferase inhibitor, 5-aza-2'-deoxycytidine (Decitabine) has limited anti-tumor efficacy, yet it induces the expression of many genes, including CTAs that are normally silenced in the healthy adult tissues. In this study, the presentation of many new HLA peptides derived from CTAs and induced by Decitabine was demonstrated in three human Glioblastoma cell lines. Such presentation of CTA-derived HLA peptides can be exploited for development of new treatment modalities, combining drug treatment with anti-CTA targeted immunotherapy. The Decitabine-induced HLA peptidomes include many CTAs that are not normally detected in healthy tissues or in cancer cells, unless treated with the drug. In addition, the study included large-scale analyses of the simultaneous effects of Decitabine on the transcriptomes, proteomes and HLA peptidomes of the human Glioblastoma cells. It demonstrates the poor correlations between these three levels of gene expression, both in their total levels and in their response to the drug.
|
| |
|
| Overall design |
The transcriptomes, proteomes and HLA peptidomes of the U-87, T98G and LNT-229 GBM human cell lines were analyzed before and after treatment with Decitabine. Overall, the RNA-Seq transcriptome analyses resulted in the identification of above 26000 transcripts, the proteome analyses identified about 7500 proteins and the HLA class I peptidome analyses resulted in above 25000 identified HLA peptides. Two biological repetitions of the transcriptome, three of the proteome and three of the HLA peptidome were performed with each of the cell lines and treatment, resulting in highly reproducible datasets.
|
| |
|
| Contributor(s) |
Shraibman B, Kadosh DM, Barnea E, Admon A |
| Citation(s) |
27412690 |
| |
| Submission date |
Apr 11, 2016 |
| Last update date |
Nov 25, 2019 |
| Contact name |
Arie Admon |
| E-mail(s) |
admon@tx.technion.ac.il
|
| Organization name |
Technion - Israel Institute of Technology, Haifa, Israel
|
| Department |
Department of Biology
|
| Street address |
Kiryat Technion- Emerson building
|
| City |
Haifa |
| State/province |
select a state |
| ZIP/Postal code |
320000 |
| Country |
Israel |
| |
|
| Platforms (1) |
| GPL16791 |
Illumina HiSeq 2500 (Homo sapiens) |
|
| Samples (12)
|
|
| Relations |
| BioProject |
PRJNA318019 |
| SRA |
SRP073103 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE80137_normalized_counts-source.txt.gz |
2.2 Mb |
(ftp)(http) |
TXT |
| GSE80137_normalized_counts-source.xlsx |
7.8 Mb |
(ftp)(http) |
XLSX |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...